DRKS00022267已完成4 期
OrkambiKIDS: Impact of CFTR-modulation with Lumacftor/Ivacaftor on the intestinal and respiratory microbiome and microbial metabolites in children aged 2 to 12 with cystic fibrosis - OrkambiKIDS
Children's Hospital, University medical center Mainz0 个研究点目标入组 8 人开始时间: 2020年10月26日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 2 Years 至 12 Years（—）
- 性别
- All
入选标准
- •Confirmed CF-diagnosis and mutation
- •Planned to start medication with Lumacftor/Ivacaftor
- •Written informed consent from parent or legal guardian
排除标准
- •Comorbidity which exclude therapy with Lumacaftor/Ivacaftor (e.g liver or renal insufficiency)
- •Clinically significant abnormality
- •Respiratory infection at the start of treatment
- •Pulmonary infection with resistant strain of bacteria
研究者
相似试验
已完成
不适用
Impact of CFTR-modulation with elexacaftor/tezacaftor/ivacaftor on the exercise capacity, intestinal and respiratory microbiome, microbial and inflammatory metabolites in cystic fibrosisE84.0Cystic fibrosis with pulmonary manifestationsDRKS00023862Zentrum für Kinder- und Jugendmedizin der Universitätsmedizin Mainz84
终止
4 期
Functional Respiratory Imaging and Orkambi in CFCystic FibrosisNCT03956589University Hospital, Antwerp12
进行中（未招募）
1 期
Study of the effects of combined treatment with the CFTR corrector ivacaftor and IV antibiotics on infection in CF.Cystic fibrosisEUCTR2016-001785-29-IESt. Vincent's University Hospital
已完成
不适用
Effect of One Year Elexacaftor-tezacaftor-ivacaftor TreatmentCystic FibrosisNCT06331000University Hospital, Strasbourg, France184
招募中
早期 1 期
Personalized Theratyping TrialCystic FibrosisNCT03587961George Solomon20